We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with bullous pemphigoid treated with IL-2 had ...

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and stopping clinical development of its lead program to hunker down and seek ...

There are conflicts that have been seen so many times in gaming that they almost become background noise. World War 2 in particular almost has become a default setting, something that may be robbing ...

Mural Oncology, Alkermes’ cancer spinoff, has officially landed with $275 million in funding and a mission to develop an interleukin-2 (IL-2) candidate for solid tumors. Alkermes announced the plan to ...

Results from Phase 1a portion of trial show first-in-class α/β biased IL-2 has potential to decouple efficacy and toxicity of IL-2 First dose expansion cohorts in Phase 1b portion of trial will ...

Interleukin-2 (IL-2) is a cytokine, a type of immune system signaling molecule, that plays a crucial role in the body's response to microbial infections and in distinguishing between self and non-self ...